Lataa...
FTC Versus Congress: The Biosimilars Debate
A Federal Trade Commission report dismissed the need for a period of market exclusivity for brand-name biologics that may face follow-on competition. The authors argue that the FTC’s conclusion –that patent protection alone will fuel biotech R&D after passage of follow-on legislation – is shaky....
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioCommunications LLC
2009
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2799095/ https://ncbi.nlm.nih.gov/pubmed/22478787 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|